As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Medicus Pharma Ltd. The largest reported stake is Bokhari, Raza's, at 5.3%. 7 filings are on record since August 12, 2025 (Schedule 13D, September 14, 2026).
Sell to companies like Medicus Pharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Melani Kenneth R. · Sole voting: 3,248,741 · Shared voting: 0 · Sole dispositive: 3,248,741 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-16
- · Reporting person: Bokhari, Raza · Sole voting: 4,066,176 · Shared voting: 793,173 · Sole dispositive: 4,066,176 · Shared dispositive: 793,173 · SCHEDULE 13D, 2026-09-14
- · Holder: Raju Ajay · Percent: 3.7% · SCHEDULE 13G/A
- · Holder: Bokhari Raza · Percent: 4.8% · SCHEDULE 13G/A
- · Holder: Armistice Capital, LLC · Percent: 4.99% · SCHEDULE 13G/A
Medicus Pharma Ltd. has 7 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bokhari, Raza | 5.3% | 4,859,349 | SCHEDULE 13D, 2026-09-14 | 2026-09-04 |
| Armistice Capital, LLC | 4.99% | 935,724 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 4.5% | 800,952 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 | |
| 3.7% | 2,031,250 | SCHEDULE 13G/A, 2026-05-05 | 2026-03-31 | |
| 3.6% | 3,248,741 | SCHEDULE 13G/A, 2026-10-16 | 2026-09-30 |
Holding shares or following this stake? See who's behind Medicus Pharma Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Medicus Pharma Ltd. and the records around it.
Medicus Pharma Ltd. elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Medicus Pharma Ltd.
Get an email when Medicus Pharma Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Medicus Pharma Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Medicus Pharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Medicus Pharma Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bokhari, Raza | 4,066,176 | 793,173 | 4,066,176 | 793,173 | SCHEDULE 13D, 2026-09-14 |
| RBx Capital, LP | 0 | 793,173 | 0 | 793,173 | SCHEDULE 13D, 2026-09-14 |
| Melani Kenneth R. | 3,248,741 | 0 | 3,248,741 | 0 | SCHEDULE 13G/A, 2026-10-16 |
| Velocity Fund Partners, LP | 2,839,330 | 0 | 2,839,330 | 0 | SCHEDULE 13G/A, 2026-10-16 |
The latest filing identifies Medicus Pharma Ltd. by CUSIP 58471K301 and gives its principal executive office as 300 CONSHOHOCKEN STATE RD., SUITE 200, W. CONSHOHOCKEN, PA 19428 (SCHEDULE 13G/A, 2026-10-16).
What the percentages are based on
See Row (11) of each Reporting Person's cover page. The percentages used herein are calculated based upon an aggregate of 89,762,721common shares reported to be outstanding as of September 10, 2026, as reflected in the Report on Schedule 13D filed by the Company's Executive Chairman & CEO on September 14, 2026.Melani Kenneth R., SCHEDULE 13G/A, 2026-10-16
Source of funds (Item 3)
The securities reported herein as beneficially owned by Dr. Bokhari include (i) 1,125,000 common shares issuable upon the exercise of stock options that are currently exercisable or will become exercisable within 60 days of the date hereof and (ii) 2,941,176 common shares. Such securities were granted to Dr. Bokhari by the Issuer as compensation for his services as an officer and director of the Issuer, and no cash consideration was paid by Dr. Bokhari in connection with the grant of such securities.Bokhari, Raza, SCHEDULE 13D, 2026-09-14
Purpose of Transaction (Item 4)
Bokhari, Raza
The Reporting Persons hold the securities reported herein for investment purposes and in the capacities further described below. Dr. Bokhari acquired, and holds, such securities both directly, and through his control of RBx Capital, LP, as applicable, in connection with his service as Executive Chairman and Chief Executive Officer of the Issuer, and as an initial investor in the securities of the Issuer at the time of its reverse take-over transaction as described in the Issuer's filings with the Commission. In his capacity as Executive Chairman and Chief Executive Officer of the Issuer, Dr. Bokhari participates in the management and direction of the business and affairs of the Issuer and, in that capacity, regularly considers, formulates and discusses with other members of management and with the board of directors of the Issuer, and votes upon as a director, matters relating to the Issuer's business, operations, strategy, capitalization, financing arrangements, dividend policy, board and management composition, corporate structure and strategic alternatives, including matters of the types described in clauses (a) through (j) of Item 4 of Schedule 13D. Dr. Bokhari may take such actions in his capacity as an officer and director of the Issuer, in each case subject to his fiduciary duties to the Issuer and its shareholders. Each Reporting Person intends to review its investment in the Issuer on a continuing basis and, depending upon various factors, including the Issuer's …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | John Hathaway | 4.5% | SCHEDULE 13G/A |
| 2025-08-12 | Melani Kenneth R. | 18.2% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-01-05 | Bokhari Raza | 4.8% | SCHEDULE 13G/A |
| 2026-05-05 | Raju Ajay | 3.7% | SCHEDULE 13G/A |
| 2026-09-14 | Bokhari, Raza | 5.3% | SCHEDULE 13D |
| 2026-10-16 | Melani Kenneth R. | 3.6% | SCHEDULE 13G/A |
Questions about who owns Medicus Pharma Ltd.
Who owns Medicus Pharma Ltd.?
On this page, one holder's latest ownership filing reports 5% or more of Medicus Pharma Ltd.: Bokhari, Raza (5.3%, Schedule 13D, filed 2026-09-14).
When did Bokhari, Raza buy into Medicus Pharma Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Bokhari, Raza on this page is the Schedule 13D, filed 2026-09-14, reporting 5.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Medicus Pharma Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.